Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool aims to make cancer treatment safer for seniors

NCT ID NCT07484932

Recruiting now Knowledge-focused Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new tool called TRTRM that predicts which older cancer patients are at high risk for severe side effects from treatment. Researchers will use the tool to adjust drug doses and monitoring for patients aged 65 and older with solid tumors. The goal is to see if this approach reduces serious side effects compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TRTRM-guided risk-stratified treatment strategy
What this could lead to
If successful, this tool could help doctors personalize cancer treatment for older patients, reducing severe side effects while maintaining effectiveness.
What could go wrong
This is a relatively early-stage trial with 400 participants, and the tool may not work as well in broader populations or with newer cancer therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer cancer digestive system cancer lung cancer neoplasm prostate cancer uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER (SOLID TUMORS) GERIATRIC ONCOLOGY

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong SAR

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.